Vanguard Group
XLO icon

Vanguard Group’s Xilio Therapeutics XLO Stock Holding History

Vanguard Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$804K Hold
89,692
– – ﹤0.01% 3832
2025
Q3 		$1.06M Buy
89,692
+7,476
+9% +$74.8K ﹤0.01% 3772
2025
Q2 		$783K Buy
82,216
+1,093
+1% +$11.5K ﹤0.01% 3819
2025
Q1 		$822K Buy
81,123
+16,656
+26% +$209K ﹤0.01% 3770
2024
Q4 		$862K Hold
64,467
– – ﹤0.01% 3810
2024
Q3 		$711K Hold
64,467
– – ﹤0.01% 3873
2024
Q2 		$855K Hold
64,467
– – ﹤0.01% 3852
2024
Q1 		$975K Hold
64,467
– – ﹤0.01% 3825
2023
Q4 		$496K Buy
64,467
+870
+1% +$17.2K ﹤0.01% 4029
2023
Q3 		$1.88M Hold
63,597
– – ﹤0.01% 3610
2023
Q2 		$2.33M Hold
63,597
– – ﹤0.01% 3607
2023
Q1 		$2.82M Hold
63,597
– – ﹤0.01% 3552
2022
Q4 		$2.4M Sell
63,597
-84
-0.1% -$2.83K ﹤0.01% 3600
2022
Q3 		$2.6M Buy
63,681
+33,741
+113% +$1.31M ﹤0.01% 3637
2022
Q2 		$1.22M Buy
29,940
+198
+0.7% +$10.5K ﹤0.01% 4014
2022
Q1 		$2.94M Sell
29,742
-560
-2% -$88.6K ﹤0.01% 3786
2021
Q4 		$6.79M Buy
+30,302
New +$7.23M ﹤0.01% 3445

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's XLO Position: Q4 2025 in Review

Vanguard Group held its Xilio Therapeutics (XLO) position steady in Q4 2025 at 89,692 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #3832.

Vanguard Group first reported a position in XLO in Q4 2021 and has held it in 17 quarters since. The position peaked at $6.79M in Q4 2021. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • Vanguard Group held 89,692 shares of Xilio Therapeutics worth $804K as of Q4 2025.
  • Vanguard Group left its Xilio Therapeutics share count unchanged in Q4 2025.
  • Xilio Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3832 holding.
  • Vanguard Group first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Xilio Therapeutics position peaked at $6.79M in Q4 2021.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.